Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : DS03090629
Catalog No.: PC-49634Not For Human Use, Lab Use Only.
DS03090629 is a potent, selective, ATP-competitive and orally available MEK1/2 inhibitor, shows high affinity for the MEK protein regardless of its phosphorylation status (npMEK (inactive) Kd=0.11 nM, and pMEK (active) Kd=0.15 nM).
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
DS03090629 is a potent, selective, ATP-competitive and orally available MEK1/2 inhibitor, shows high affinity for the MEK protein regardless of its phosphorylation status (npMEK (inactive) Kd=0.11 nM, and pMEK (active) Kd=0.15 nM).
DS03090629 is effective for BRAF-overexpressing melanoma cell lines (A375_mock, IC50=37.1 nM; A375_BRAF, IC50=74.3 nM).
DS03090629 exhibits tendencies to retain inhibitory activities against both WT MEK1 and F53L mutant against wild-type pMEK1 and mutated pMEK1 in a cell-free enzymatic assays.
DS03090629 is effective against not only BRAF-overexpressing cancers, but also MEK1-mutated cancer cells.
DS03090629 also exhibits superior efficacy against a melanoma cell line expressing mutant MEK1 protein compared with dabrafenib and trametinib.
DS03090629 (75 mg/kg, mpk, QD) combined with dabrafenib significantly inhibited ERK phosphorylation, induced tumor regression in the A375_mock or A375_BRAF xenograft models.
| M.Wt | 463.97 | |
| Formula | C25H26ClN5O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Kohei Takano, et al. Mol Cancer Ther. 2023 Jan 9;MCT-22-0306.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
